Expression and clinical significance of SMYD3 in rectal cancer
10.3760/cma.j.cn121382-20191207-00303
- VernacularTitle:直肠癌组织中SMYD3的表达及临床意义
- Author:
Bingtao LI
1
;
Xianli LIU
Author Information
1. 河南科技大学临床医学院，河南科技大学第一附属医院，洛阳 471003
- From:
International Journal of Biomedical Engineering
2020;43(3):182-187
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the expression level and clinical significance of SET and MYND domain-containingprotein 3(SMYD3) in rectal cancer tissues.Methods:Immunohistochemistry and Western blot were used to detect the expression of SMYD3 in 64 cases of rectal cancer tissues and corresponding adjacent tissues. The relationship between SMYD3 expression and clinicopathological characteristics and prognosis of rectal cancer were analyzed.Results:The expression rate of SMYD3 in rectal cancer tissue was 60.94%, which was higher than that in adjacent tissues by 14.06%, and the difference was statistically significant (χ 2=30.00, P<0.05). The expression of SMYD3 in rectal cancer tissue has no correlation with the patient's age, gender, and degree of tissue differentiation (all P>0.05), but has correlation with TNM staging, depth of invasion and lymph node metastasis (all P<0.05). The prognosis of the rectal cancer patients with positive expression of SMYD3 was worse than that with negative expression ( P<0.05). The expression of SMYD3 protein in rectal cancer tissues (1.26±0.31) was significantly higher than that in the corresponding adjacent tissues (0.55±0.22) ( t=11.95, P<0.05). Conclusions:The increased expression of SMYD3 is related to the occurrence and development of rectal cancer, and its expression level can be used as an index for judging the malignancy of rectal cancer and evaluating its prognosis. The results of this study show that SMYD3 is involved in the occurrence and development of rectal cancer. The results of this study can provide a basis for SMYD3 as a new target for rectal cancer targeted therapy and a prognostic criterion.
